DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ismotic (Isosorbide) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

ISMOTIC SUMMARY

ISMOTIC®
(isosorbide solution)
45% w/v Solution

ISMOTIC® is a 45% w/v solution of isosorbide in a vanilla-mint flavored vehicle.

ISMOTIC (isosorbide) is indicated for the following:

For the short-term reduction of intraocular pressure. May be used prior to and after intraocular surgery. May be used to interrupt an acute attack of glaucoma.


See all Ismotic indications & dosage >>

ISMOTIC NEWS HIGHLIGHTS

Media Articles Related to Ismotic (Isosorbide)

isosorbide mononitrate, Imdur, Ismo, Monoket
Source: MedicineNet isosorbide dinitrate Specialty [2009.03.26]
Title: isosorbide mononitrate, Imdur, Ismo, Monoket
Category: Medications
Created: 12/31/1997
Last Editorial Review: 3/26/2009

isosorbide dinitrate, Isordil Titradose, Dilatrate-SR, Isochron
Source: MedicineNet isosorbide mononitrate Specialty [2009.02.20]
Title: isosorbide dinitrate, Isordil Titradose, Dilatrate-SR, Isochron
Category: Medications
Created: 12/31/1997
Last Editorial Review: 2/20/2009

more news >>

Published Studies Related to Ismotic (Isosorbide)

Cervical priming in the first trimester: morphological and biochemical effects of misoprostol and isosorbide mononitrate. [2009]
OBJECTIVE: To evaluate morphological changes and inflammatory events in the uterine cervix following presurgical treatment with the prostaglandin analogue misoprostol or the nitric oxide donor isosorbide [generic for Ismotic] mononitrate (IMN). DESIGN: Experimental study. SETTINGS: Sahlgrenska University Hospital, Gothenburg, Sweden. POPULATION OF SAMPLE: Primigravid women (n=32) scheduled for surgical termination of first trimester pregnancy, treated vaginally overnight with either misoprostol (200 microg), IMN (40 mg) or no treatment (controls)... CONCLUSION: The study demonstrates that misoprostol as well as IMN induces morphological changes and inflammatory events of the cervix. Changes of the collagen network were more pronounced in samples obtained from women treated with misoprostol compared to IMN.

Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis. [2008.12]
OBJECTIVE: To compare the effectiveness, safety, and affordability of isosorbide [generic for Ismotic] mononitrate with alendronate for postmenopausal osteoporosis... CONCLUSION: Isosorbide mononitrate is comparable to alendronate. Nitric oxide donors may be an effective and affordable therapy to improve bone mineral density.

Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis. [2008.09.20]
OBJECTIVE: To compare the effectiveness, safety, and affordability of isosorbide [generic for Ismotic] mononitrate with alendronate for postmenopausal osteoporosis... CONCLUSION: Isosorbide mononitrate is comparable to alendronate. Nitric oxide donors may be an effective and affordable therapy to improve bone mineral density.

Outpatient cervical ripening with nitric oxide donor isosorbide mononitrate prior to induction of labor. [2008.04]
Objective: To examine the effectiveness and safety of outpatient vaginal administration of isosorbide [generic for Ismotic] mononitrate (IMN) to induce cervical ripening. Methods: A prospective, double-blind, placebo-controlled, randomized clinical trial was conducted on 102 singleton term pregnant women with unfavorable cervices who were randomly assigned to receive outpatient intravaginal IMN or placebo before admission for induction of labor.

Pentaerythrityl tetranitrate and nitroglycerin, but not isosorbide mononitrate, prevent endothelial dysfunction induced by ischemia and reperfusion. [2007.09]
CONCLUSIONS: We show important differences among organic nitrates in their capacity to prevent IR-induced endothelial dysfunction. GTN and PETN, but not ISMN, have this preconditioning effect. The potential clinical implications of these data warrant further investigation.

more studies >>

Clinical Trials Related to Ismotic (Isosorbide)

Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma [Active, not recruiting]
This is a phase II clinical trial in patients who have not received systemic treatment for follicular non-Hodgkin's lymphoma. The study combines rituximab, an approved drug for this disease, with AT-101, an experimental drug. The hypothesis is that by adding AT-101 to the rituximab regimen, improvement to patients' response to the treatment will be observed verses rituximab alone.

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer [Active, not recruiting]
This is an open label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with topotecan in relapsed/refractory small cell lung cancer

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer [Recruiting]
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate cancer that are either chemotherapy naive or have received and progressed on a docetaxel containing regimen,

A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer [Recruiting]
This is a double- blind, multicenter, randomized Phase II study to evaluate the efficacy and safety of AT-101 in combination with docetaxel in relapsed/refractory non-small cell lung cancer

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) [Recruiting]
This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo in the treatment of chemotherapy-naïve metastatic hormone-refractory prostate cancer, who have received hormonal therapy but not chemotherapy.

more trials >>

Page last updated: 2009-03-26

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009